Stratipath and PathAI Partner to Expand Access to AI-based Precision Diagnostics
Stratipath Breast will be available within PathAI’s AISight® Dx Image Management System (IMS)
Stratipath and Visiopharm partner to advance implementation of AI-Powered Breast Cancer Diagnostics
Stratipath and Visiopharm, today announced a strategic collaboration to combine their regulatory compliant solutions for enhanced breast cancer diagnostics.
First world health tech: Press Release Stratipath releases biopsy capability for its CE-IVD marked AI diagnostic solution, Stratipath Breast
First world health tech: Press Release Stratipath releases biopsy capability for its CE-IVD marked AI diagnostic solution, Stratipath Breast
Region Östergötland Implements AI-Powered Stratipath Breast to Enhance Breast Cancer Diagnostics
Linköping University Hospital and Region Östergötland have chosen to implement Stratipath Breast as part of their clinical routine for early breast cancer diagnostics.
ESMO daily: AI integration in breast cancer – a long way ahead?
The ESMO Daily Reporter recently published a summary of the insightful discussions on AI in oncology, a field that is transforming rapidly. Our very own co-founder and CTO, Dr. Mattias Rantalainen, chaired and contributed to this important track.
Stratipath team contributes to foundation model research published in Nature
A method for spatial interpretation of weakly supervised deep learning models in computational pathology
Region Uppsala chooses to implement AI-based risk profiling with Stratipath Breast
Region Uppsala, Sweden’s fourth largest healthcare region, has chosen to implement Stratipath Breast, an AI-based risk profiling solution for breast cancer, in clinical use.
Stratipath releases biopsy capability for its CE-IVD marked AI diagnostic solution, Stratipath Breast
Stratipath releases biopsy capability for its CE-IVD marked AI diagnostic solution, Stratipath Breast. The new capability strengthens clinical decision-making for neoadjuvant therapy.
Pharma Times: Diagnexia and Stratipath link up brings AI breast cancer diagnostics to UK
Diagnexia has announced a partnership with Stratipath AB to bring Stratipath Breast, an AI-based prognostic risk profiling tool, to healthcare providers across the UK and Europe.
This collaboration integrates Stratipath’s technology with Diagnexia’s digital pathology network, providing faster, more precise cancer diagnostics. The partnership aims to improve decision-making for breast cancer treatments.
Diagnexia and Stratipath Partner to Expand AI-Based Cancer Precision Diagnostics Across the UK and Europe
Diagnexia, and Stratipath AB are pleased to announce a strategic partnership. This collaboration will bring Stratipath Breast, an AI-based prognostic risk profiling tool for invasive breast cancer, to pathology laboratories, hospitals, and healthcare providers across the UK and Europe.